B cells as biomarkers: Predicting immune checkpoint therapy adverse events

Shannon M. Liudahl, Lisa M. Coussens

Research output: Contribution to journalReview article

  • 1 Citations

Abstract

Immune checkpoint inhibitors are becoming a cornerstone of cancer immunotherapy as a result of their clinical success in relieving immune suppression and driving durable antitumor T cell responses in certain subsets of patients. Unfortunately, checkpoint inhibition is also associated with treatment-related toxicities that result in a myriad of side effects, ranging from mild and manageable to severe and debilitating. In this issue of the JCI, Das and colleagues report an association between early therapy-induced changes in circulating B cells and an increased risk of high-grade immune-related adverse events (IRAEs) in patients treated with checkpoint inhibitors that target cytotoxic T lymphocyte–associated antigen-4 (CTLA4) and programmed cell death protein 1 (PD1). These findings identify potential predictive biomarkers for high-grade IRAEs that May be leveraged to improve patient monitoring and May prompt new treatment strategies to prevent IRAEs.

LanguageEnglish (US)
Pages577-579
Number of pages3
JournalJournal of Clinical Investigation
Volume128
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Programmed Cell Death 1 Receptor
B-Lymphocytes
Biomarkers
CTLA-4 Antigen
Physiologic Monitoring
Secondary Prevention
Immunotherapy
T-Lymphocytes
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

B cells as biomarkers : Predicting immune checkpoint therapy adverse events. / Liudahl, Shannon M.; Coussens, Lisa M.

In: Journal of Clinical Investigation, Vol. 128, No. 2, 01.02.2018, p. 577-579.

Research output: Contribution to journalReview article

@article{fe78a7e13c7647c1a16bdc5914f2479a,
title = "B cells as biomarkers: Predicting immune checkpoint therapy adverse events",
abstract = "Immune checkpoint inhibitors are becoming a cornerstone of cancer immunotherapy as a result of their clinical success in relieving immune suppression and driving durable antitumor T cell responses in certain subsets of patients. Unfortunately, checkpoint inhibition is also associated with treatment-related toxicities that result in a myriad of side effects, ranging from mild and manageable to severe and debilitating. In this issue of the JCI, Das and colleagues report an association between early therapy-induced changes in circulating B cells and an increased risk of high-grade immune-related adverse events (IRAEs) in patients treated with checkpoint inhibitors that target cytotoxic T lymphocyte–associated antigen-4 (CTLA4) and programmed cell death protein 1 (PD1). These findings identify potential predictive biomarkers for high-grade IRAEs that May be leveraged to improve patient monitoring and May prompt new treatment strategies to prevent IRAEs.",
author = "Liudahl, {Shannon M.} and Coussens, {Lisa M.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1172/JCI99036",
language = "English (US)",
volume = "128",
pages = "577--579",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

TY - JOUR

T1 - B cells as biomarkers

T2 - Journal of Clinical Investigation

AU - Liudahl,Shannon M.

AU - Coussens,Lisa M.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Immune checkpoint inhibitors are becoming a cornerstone of cancer immunotherapy as a result of their clinical success in relieving immune suppression and driving durable antitumor T cell responses in certain subsets of patients. Unfortunately, checkpoint inhibition is also associated with treatment-related toxicities that result in a myriad of side effects, ranging from mild and manageable to severe and debilitating. In this issue of the JCI, Das and colleagues report an association between early therapy-induced changes in circulating B cells and an increased risk of high-grade immune-related adverse events (IRAEs) in patients treated with checkpoint inhibitors that target cytotoxic T lymphocyte–associated antigen-4 (CTLA4) and programmed cell death protein 1 (PD1). These findings identify potential predictive biomarkers for high-grade IRAEs that May be leveraged to improve patient monitoring and May prompt new treatment strategies to prevent IRAEs.

AB - Immune checkpoint inhibitors are becoming a cornerstone of cancer immunotherapy as a result of their clinical success in relieving immune suppression and driving durable antitumor T cell responses in certain subsets of patients. Unfortunately, checkpoint inhibition is also associated with treatment-related toxicities that result in a myriad of side effects, ranging from mild and manageable to severe and debilitating. In this issue of the JCI, Das and colleagues report an association between early therapy-induced changes in circulating B cells and an increased risk of high-grade immune-related adverse events (IRAEs) in patients treated with checkpoint inhibitors that target cytotoxic T lymphocyte–associated antigen-4 (CTLA4) and programmed cell death protein 1 (PD1). These findings identify potential predictive biomarkers for high-grade IRAEs that May be leveraged to improve patient monitoring and May prompt new treatment strategies to prevent IRAEs.

UR - http://www.scopus.com/inward/record.url?scp=85041476675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041476675&partnerID=8YFLogxK

U2 - 10.1172/JCI99036

DO - 10.1172/JCI99036

M3 - Review article

VL - 128

SP - 577

EP - 579

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -